medigraphic.com
ISSN 1727-897X (Electronic)

2022, Number 5

<< Back Next >>

Medisur 2022; 20 (5)

Ketamine in cancer pain management

González PS, Báez MWE, López-Muñoz F

Language: Spanish
References: 35
Page: 956-967
PDF size: 938.76 Kb.


ABSTRACT

Background The growing demand for new analgesics and neuromodulatory substances in general for the treatment of pain, makes it necessary to standardize their use. In the case of ketamine, most research revolves around its use in treating acute pain in medical emergencies.
Objective to carry out a review of the current scientific literature on the potentialities of ketamine in the treatment of cancer pain.
Methods a descriptive study was carried out, with a non-experimental, longitudinal design, which, through a documentary review on the subject of ketamine in the management of cancer pain, allowed the development of a systematic review of scientific articles published from 2010 to 2019. The Preferred Reporting Items for Systematic reviews and Meta-Analyses methodology was applied, according to which the extraction, search and eligibility process of the articles was developed.
Results of a total of 250 articles found in the initial search, 6 were selected, considering the sample selection criteria. The ones that were most related to the output of articles were the overlap effect and the temporal effect. Positive responses were obtained by any route of administration of ketamine, except topical, a variant applied precisely in the largest study.
Conclusion according to the evidence analyzed in this study, the effectiveness of ketamine is not confirmed in three of the six studies evaluated. However, in subanesthetic doses, its use could still be considered for the management of cancer pain.


REFERENCES

  1. International Agency for Reasearch on Cancer WHO. All cancers[Internet]. Lyon: Cancer Today-IARC; 2018[citado 15/02/2022]. Available from: Available from: https://gco.iarc.fr/today/home https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf 1.

  2. Singh V, Gillespie T, Harvey D. Intranasal Ketamine and Its Potential Role in Cancer-Related Pain. Pharmacotherapy. 2018;38(3):390-401.

  3. Allen CA, Ivester JR. Ketamine for Pain Management-Side Effects & Potential Adverse Events. Pain Manag Nurs. 2017;18(6):372-7.

  4. World Health Organization. Palliative care[Internet]. Geneva: WHO; 2022[citado 15/02/2022]. Disponible en: Disponible en: https://www.who.int/cancer/palliative/painladder/en/ 4.

  5. Murillo M, Valentín V. Diagnóstico y tratamiento del dolor oncológico. Atención primaria. 2018;40(1):[aprox. 2p]. Disponible en: https://www.elsevier.es/en-revista-atencion-primaria-27-articulo-diagnostico-tratamiento-del-dolor-oncologico-131143325.

  6. Fan W, Yang H, Sun Y, Zhang J, Li G, Zheng Y, Liu Y. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. Oncotarget. 2017;8(2):2356-60.

  7. Potter DE, Choudhury M. Ketamine: repurposing and redefining a multifaceted drug. Drug Discov Today. 2014;19(12):1848-54.

  8. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017;6(6):CD003351.

  9. Chen L, Malek T. Follow me down the K-hole: ketamine and its modern applications. Crit Care Nurs Q. 2015;38(2):211-6.

  10. Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ. Classics in Chemical Neuroscience: Ketamine. ACS Chem Neurosci. 2017;8(6):1122-34.

  11. Castañeda AM, Choi JK, Lee CS, Oh E, Kim Y, Moon JY, et al. Ketamine infusion therapy for chronic pain management in South Korea: A national survey for pain physicians with a narrative review. Medicine (Baltimore). 2018;97(32):e11709.

  12. Carrillo O, Medina PJ. Entendiendo el concepto de dolor refractario a opioides. Rev Mex Anestesiol[Internet]. 2017[citado 15/02/2022];40(2):[aprox. 26p]. Disponible en: https://www.medigraphic.com/pdfs/rma/cma-2017/cma172d.pdf12.

  13. Ministerio de Salud Pública. Tratamiento del dolor oncológico en adultos. Guía de ráctica Clínica[Internet]. Quito: Dirección Nacional de Normatización; 2017[citado 15/02/2022]. Disponible en: Disponible en: https://www.salud.gob.ec/wp-content/uploads/2017/06/Dolor-oncol%C3%B3gico-GPC-final-12-12-2016-1.pdf 13.

  14. Sassano S, Baron D, Juarez G, Esmaili N, Gold M. A review of ketamine abuse and diversion. Depress Anxiety. 2016;33(8):718-27.

  15. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

  16. Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807-14.

  17. Salas S, Frasca M, Planchet B, Burucoa B, Pascal M, Lapiana JM, et al. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med. 2012;15(3):287-93.

  18. Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A. Treatment of severe mucositis pain with oral ketamine mouthwash. Support Care Cancer. 2017;25(7):2215-9.

  19. Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30(29):3611-7.

  20. Benítez MA, Salinas A, González T, Feria M. A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio. J Pain Symptom Manage. 2011;41(6):1098-105.

  21. Jonkman K, van der Schrier R, van Velzen M, Aarts L, Olofsen E, Sarton E, et al. Differential role of nitric oxide in the psychedelic symptoms induced by racemic ketamine and esketamine in human volunteers. Br J Anaesth. 2018;120(5):1009-18.

  22. Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharmacol Sin. 2016;37(7):865-72.

  23. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059-77.

  24. Quibell R, Fallon M, Mihalyo M, Twycross R, Wilcock A. Ketamine. J Pain Symptom Manage. 2015;50(2):268-78.

  25. Mercadante S. Topical amitriptyline and ketamine for the treatment of neuropathic pain. Expert Rev Neurother. 2015;15(11):1249-53.

  26. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521-46.

  27. Jouguelet-Lacoste J, La Colla L, Schilling D, Chelly JE. The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med. 2015;16(2):383-403.

  28. Xu J, Lei H. Ketamine-an update on its clinical uses and abuses. CNS Neurosci Ther. 2014;20(12):1015-20.

  29. Wong GL, Tam YH, Ng CF, Chan AW, Choi PC, Chu WC, et al. Liver injury is common among chronic abusers of ketamine. Clin Gastroenterol Hepatol. 2014;12(10):1759-62.e1.

  30. Iacobucci GJ, Visnjevac O, Pourafkari L, Nader ND. Ketamine: An Update on Cellular and Subcellular Mechanisms with Implications for Clinical Practice. Pain Physician. 2017;20(2):E285-301.

  31. Zhou N, Fu Z, Li H, Wang K. Ketamine, as adjuvant analgesics for patients with refractory cancer pain, does affect IL-2/IFN-? expression of T cells in vitro?: A prospective, randomized, double-blind study. Medicine (Baltimore). 2017;96(16):e6639.

  32. Hou M, Zhou NB, Li H, Wang BS, Wang XQ, Wang XW, et al. Morphine and ketamine inhibit immune function of gastric cancer patients by increasing percentage of CD4(+)CD25(+)Foxp3(+) regulatory T cells in vitro. J Surg Res. 2016;203(2):306-12.

  33. Winegarden J, Carr DB, Bradshaw YS. Intravenous Ketamine for Rapid Opioid Dose Reduction, Reversal of Opioid-Induced Neurotoxicity, and Pain Control in Terminal Care: Case Report and Literature Review. Pain Med. 2016;17(4):644-9.

  34. Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Support Palliat Care. 2017;11(2):88-92.

  35. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357-67.




2020     |     www.medigraphic.com